Rhapsido access guide: country options for cross-border named-patient access
Editorial and clinical review: Reserve Meds clinical and regulatory team. Last reviewed 2026-06-04.
About Rhapsido
Rhapsido (remibrutinib) is an oral Bruton tyrosine kinase (BTK) inhibitor approved by the US Food and Drug Administration in September 2025 for chronic spontaneous urticaria. The current FDA label is available at accessdata.fda.gov. Rhapsido is marketed by Novartis. Reserve Meds coordinates US-sourced cross-border access to Rhapsido under the named-patient and personal-import framework that governs reference-authority-approved medicines in the patient jurisdiction, with chain-of-custody documentation under the US Drug Supply Chain Security Act (DSCSA). The country-specific access guides listed below set out the regulatory pathway, the tertiary referral context, the documentation bundle the treating physician of record submits to the regulator, and how to request a written quote for Rhapsido in each jurisdiction Reserve Meds has authored.
Rhapsido country-specific access guides
Reserve Meds has published 7 country-specific access guides for Rhapsido. Each guide covers the regulatory pathway, the tertiary referral context, the documentation package, how quotes work, and the operational sequence Reserve Meds coordinates for that jurisdiction.
Bahrain
Read the Bahrain access guide for Rhapsido.
Read the guideBangladesh
Read the Bangladesh access guide for Rhapsido.
Read the guideEgypt
Read the Egypt access guide for Rhapsido.
Read the guideIndia
Read the India access guide for Rhapsido.
Read the guideLebanon
Read the Lebanon access guide for Rhapsido.
Read the guideSri Lanka
Read the Sri Lanka access guide for Rhapsido.
Read the guideUAE
Read the UAE access guide for Rhapsido.
Read the guideOther countries
Reserve Meds has authored country-specific access guides for Rhapsido in the 7 jurisdictions listed above. If your country is not on this list, a lawful pathway may still be available. The Reserve Meds case team will scope your case under the same named-patient or personal-import framework that governs the published guides.
Request a Rhapsido access scope for your country
Related Reserve Meds resources
Illustrative example cases (composites, not real patients). This content is for general information and does not constitute medical advice. Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We are not the prescriber and not the dispensing pharmacy. Clinical decisions remain with your treating physician.
Editorial review: Reserve Meds clinical and regulatory team. Last reviewed 2026-06-04.
Frequently asked questions
How can I get Rhapsido if it is not approved or available in my country?
Reserve Meds coordinates US-sourced Rhapsido for patients through a legal named-patient pathway, working with your treating doctor. Your treating physician provides the prescription and clinical justification; Reserve Meds prepares the named-patient documentation for your country and arranges DSCSA-compliant US sourcing and delivery to your physician or hospital pharmacy.
Can I access Rhapsido through a named-patient import?
Often, yes. Named-patient access (sometimes called personal import) is the legal route we use for FDA-approved medicines such as Rhapsido. It is different from compassionate use, which covers investigational medicines through the manufacturer's own program; we do not supply investigational medicines. Eligibility and paperwork depend on the regulator in your country, and Reserve Meds maps the specific pathway for each market it coordinates.
Do I need a prescription to access Rhapsido through Reserve Meds?
Yes. Reserve Meds is not a pharmacy and does not prescribe. A valid prescription and clinical justification from your treating physician are required, and all clinical decisions remain with your physician.
How does Reserve Meds deliver Rhapsido to a patient?
Medicines are supplied through a US-licensed pharmaceutical wholesale partner, and Reserve Meds coordinates delivery of Rhapsido to your treating physician or hospital pharmacy, with appropriate handling for the product.
How long does it take, and what does Rhapsido cost through Reserve Meds?
After a short intake, the clinical team responds within one business day with case-specific feasibility, an indicative timeline, and a formal written quote. Cost depends on the destination, the prescribed regimen, and the duration of therapy, and is confirmed in writing before anything proceeds.
How do I start a request for Rhapsido?
Submit a 60-second intake through the Reserve Meds patient portal, or message our team on WhatsApp. We reply within one business day. On WhatsApp we usually reply the same day.